IGFBP2 Cell Death Marker in Children with Immune Thrombocytopenia

Background: Pediatric Immune thrombocytopenia (ITP) is a condition in children where the immune system attacks and destroys platelets, leading to a temporary or ongoing drop in platelet count. According to the time that thrombocytopenia lasts, ITP can be classified as “acute” which resolves before six months, versus “chronic” ITP which lasts more than 6 months- 12 months. Multicellular animals undergo apoptosis, a complicated process of regulated cell death. It involves a series of intricate processes, which rely on energy and consist of a cascade of molecular events. Multiple studies have investigated the involvement of apoptosis in individuals with ITP. Platelet apoptosis may occur as a result of autoantibodies targeting proteins on the surface of platelets.Aim of the study: We set intended to correlate insulin growth factor binding protein type-2 (IGFBP-2) levels with clinical outcome in young patients with ITP, so we could predict their outcome since diagnosis.Patients and Methods: This study is a cross-sectional study that was conducted in Fayoum governorate, the research involved a total of 40 children with newly diagnosed ITP. All Cases were subjected at presentation to thorough full history, physical examination, and laboratory investigations. IGFBP2 levels were measured using enzyme-linked immunosorbent assay (ELISA) technique. Our ITP cases were followed up to 6 months. Results: There were significant increased levels of IGFBP2 in the newly diagnosed resolved pediatric ITP cases compared to chronic ITP cases with a p-value <0.001.Conclusions: The outcome of pediatric ITP cases could be predicted using IGFBP2 apoptotic marker.